Clinical trials: Tumor Patients
Malignant Solid Tumors
A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
This is an open-label, multi-center phase 1b study to evaluate the safety and efficacy of Sirolimus for injection (albumin-bound) in patients with malignant solid tumors with TSC1 or TSC2 genetic alterations.
- Trial name
- NCT05508620
- Testing
- Sirolimus for Injection (Albumin-bound)
- Volunteers
- 270 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acute Myelogenous Leukemia
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
The primary objective of this study is to evaluate the safety of gemtuzumab ozogamicin in relapsed CD33-positive AML patients who received HSCT. If the MTD dose is not reached, 9 mg/m2 will be the maximum tested dose.
- Trial name
- NCT00044733
- Testing
- Mylotarg (gemtuzumab ozogamicin) Injection
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Generalized Myasthenia Gravis, gMG
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine…
- Trial name
- OCTAGON (NCT07221838)
- Testing
- Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone
- Where
- 12 sites in United States, Germany and 2 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Metastatic Colorectal Cancer
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
ARQ 197 or placebo in combination with irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC), in participants with wild-type KRAS alleles who have failed front-line systemic therapy, to evaluate the…
- Trial name
- NCT01075048
- Testing
- Tivantinib, Cetuximab, Irinotecan
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 131 people
- Sponsor
- Daiichi Sankyo
Advanced Malignant Tumors
A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
A Phase Ia/Ib open label，clinical study evaluating the safety, tolerability and preliminary efficacy of AK127 in combination with AK104 in patients with advanced malignant tumors
- Trial name
- NCT05868876
- Testing
- AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Akeso
Acute Leukemia
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 ([14C])-revumenib in participants with acute leukemia.
- Trial name
- NCT05406817
- Testing
- Revumenib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Syndax Pharmaceuticals
Hepatocellular Carcinoma
Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma
Chiauranib, which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
- Trial name
- NCT03245190
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Lymphocytic Leukemia, Chronic
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
This multi-center, single-arm study evaluated the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide in participants with B-cell chronic lymphocytic leukemia (CLL) and favorable somatic status.
- Trial name
- NCT01271010
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 10 sites in Russia
- Volunteers
- 89 people
- Sponsor
- Hoffmann-La Roche
Glioma
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful.
- Trial name
- NCT05916313
- Testing
- BI 764532
- Where
- 12 sites in United States, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Multiple Myeloma
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
- Trial name
- NCT07490613
- Testing
- SHR-3836 administered as multiple doses.
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Tumor, Lymphoma
To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Patients with advanced tumors diagnosed histologically or cytologically at the study center who were refractory to standard therapy or had relapsed received XNW5004 tablets
- Trial name
- NCT06558513
- Testing
- XNW5004 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Evopoint Biosciences Inc.
Solid Tumors
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
This study was to determine the maximum-tolerated dose (MTD) and/or the optimal biological dose (OBD) as well as the optimal schedule for intravenous (IV) and subcutaneous (SC) administrations of RO7172508 as monotherapy, with or…
- Trial name
- NCT03539484
- Testing
- RO7172508, Obinutuzumab, Tocilizumab
- Where
- 6 sites in Belgium, Canada and 2 more
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Advanced Unresectable or Metastatic Breast Cancer of Adults
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209…
- Trial name
- NCT07389733
- Testing
- HRS-6208 Capsule, HRS-6209 Capsule, HRS-8080 Tablet
- Where
- 2 sites in China
- Volunteers
- 180 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
- Conditions
- Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS
- Trial name
- NAVAL-1 (NCT05011058)
- Testing
- Nanatinostat in combination with valganciclovir
- Where
- 62 sites in United States, Australia and 12 more
- Volunteers
- 102 people
- Sponsor
- Viracta Therapeutics, Inc.
Moderate to Severe Ulcerative Colitis
Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo
The objectives of this study are to explore the fecal calprotectin (fC) levels of UC patients under adalimumab therapy and the correlation with their general wellbeing (Quality of Life [QoL]), workability, and disease activity.
- Trial name
- AdaProQuo (NCT02092389)
- Volunteers
- 10 people
- Sponsor
- AbbVie
Lymphoma, Refractory Solid Tumors
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
The purpose of this study is to evaluate the safety and tolerability of ASP4132 and to determine the maximum tolerated dose and recommended phase 2 dose of ASP4132.
- Conditions
- Lymphoma, Refractory Solid Tumors, Advanced Cancer
- Trial name
- NCT02383368
- Testing
- ASP4132
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Astellas Pharma Global Development, Inc.
ER+ HER2- Advanced Breast Cancer
AZD9496 First Time in Patients Ascending Dose Study
This is a phase 1 open label multicentre study of AZD9496 administered orally in patients with advanced ER+ HER2 negative breast cancer.
- Trial name
- NCT02248090
- Testing
- AZD9496
- Where
- 6 sites in United States, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Metastatic Melanoma
Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma
Autologous monocyte-derived dendritic cells pulsed with tumor lysate (PV-001-DC) will be given to a group of 3 people. If this is found to be safe, it will be given to up to 7 other people, for a total of up to 10 people in this…
- Trial name
- NCT03803397
- Testing
- PV-001-DC
- Volunteers
- 10 people
- Sponsor
- PrimeVax Immuno-Oncology Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to determine the activity of tamibarotene in participants with relapsed/refractory (R/R) AML (administered as a monotherapy or in combination with azacitidine), R/R higher-risk MDS (HR-MDS)…
- Trial name
- NCT02807558
- Testing
- Tamibarotene, Azacitidine, Daratumumab
- Where
- 26 sites in United States, France
- Volunteers
- 155 people
- Sponsor
- Syros Pharmaceuticals
Glioblastoma
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
BACKGROUND: Active immunotherapy of cancer is based on the premise that the vaccine raises a cytotoxic immune response to tumor-associated antigens, thereby destroying malignant cells without harming normal cells.
- Trial name
- NCT01403285
- Testing
- Cyclophosphamide, IMA950 plus GM-CSF, IMA950
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Immatics Biotechnologies GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.